KRAS and pancreatic neoplasm: Interestingly, deficiencies of Atg5 or Atg7 in KRas mutant-derived pancreatic cancer models inhibited progression to pancreatic duct adenocarcinoma (PDAC); however, the loss of autophagy without Trp53 no longer inhibited tumor progression but rather accelerated it.